fluorouracil has been researched along with Psoriasis in 52 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To compare the efficacy and safety of intralesional injection of 5-fluorouracil (5-FU), methotrexate (MTX), triamcinolone acetonide (TA) versus topical calcipotriol plus urea 20% in the treatment of nail psoriasis." | 9.51 | Topical calcipotriol combined with urea 20% versus intralesional injection of triamcinolone acetonide, 5-fluorouracil, and methotrexate in the treatment of nail psoriasis: A comparative study. ( Abdelmeniem, IM; El Eryan, IM; Fouda, I; Nofal, A; Omar, SS, 2022) |
| "We report use of a new weekly pulse dosing schedule of 5% fluorouracil under occlusion for topical treatment of recalcitrant psoriasis." | 9.06 | Weekly pulse dosing schedule of fluorouracil: a new topical therapy for psoriasis. ( Engelhard, C; Pearlman, DL; Youngberg, B, 1986) |
| "Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia." | 8.12 | Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022) |
| "Three patients affected with nail psoriasis of the fingers in whom the use of topical 5-fluorouracil (5-FU) led to yellow nail discoloration are reported." | 7.75 | Yellow nails as an adverse reaction to the topical use of 5-fluorouracil for the treatment of nail psoriasis. ( Fiallo, P, 2009) |
| "Psoriasis is a papulosquamous disorder that causes significant social and psychological trauma to the patient." | 5.72 | Comparative efficacy of intralesional 5 flurouracil and intralesional triamcinolone acetonide in localized plaque psoriasis. ( Attwa, E; Essam, R; Khater, MH; Selim, HM, 2022) |
| " To compare the efficacy and safety of intralesional injection of 5-fluorouracil (5-FU), methotrexate (MTX), triamcinolone acetonide (TA) versus topical calcipotriol plus urea 20% in the treatment of nail psoriasis." | 5.51 | Topical calcipotriol combined with urea 20% versus intralesional injection of triamcinolone acetonide, 5-fluorouracil, and methotrexate in the treatment of nail psoriasis: A comparative study. ( Abdelmeniem, IM; El Eryan, IM; Fouda, I; Nofal, A; Omar, SS, 2022) |
| "We report use of a new weekly pulse dosing schedule of 5% fluorouracil under occlusion for topical treatment of recalcitrant psoriasis." | 5.06 | Weekly pulse dosing schedule of fluorouracil: a new topical therapy for psoriasis. ( Engelhard, C; Pearlman, DL; Youngberg, B, 1986) |
| "Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia." | 4.12 | Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022) |
| "Three patients affected with nail psoriasis of the fingers in whom the use of topical 5-fluorouracil (5-FU) led to yellow nail discoloration are reported." | 3.75 | Yellow nails as an adverse reaction to the topical use of 5-fluorouracil for the treatment of nail psoriasis. ( Fiallo, P, 2009) |
| "Psoriasis is a chronic skin disease that affects millions of people throughout the world." | 2.44 | Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. ( Jiaravuthisan, MM; Muhn, CY; Murphy, F; Sasseville, D; Vender, RB, 2007) |
| "As with treatment of psoriasis affecting skin, relapse is common and therapies may need to be maintained or repeated." | 2.41 | Management of nail psoriasis. ( de Berker, D, 2000) |
| "Psoriasis is a papulosquamous disorder that causes significant social and psychological trauma to the patient." | 1.72 | Comparative efficacy of intralesional 5 flurouracil and intralesional triamcinolone acetonide in localized plaque psoriasis. ( Attwa, E; Essam, R; Khater, MH; Selim, HM, 2022) |
| "The typical presentation of porokeratosis of Mibelli is of a solitary plaque with a prominent raised border cleaved by a central furrow." | 1.32 | Verrucous porokeratosis of Mibelli on the buttocks mimicking psoriasis. ( Brice, SL; Fitzpatrick, JE; Wallner, JS, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (67.31) | 18.7374 |
| 1990's | 6 (11.54) | 18.2507 |
| 2000's | 7 (13.46) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Watts, K | 1 |
| Wills, C | 1 |
| Madi, A | 1 |
| Palles, C | 1 |
| Maughan, TS | 1 |
| Kaplan, R | 1 |
| Al-Tassan, NA | 1 |
| Kerr, R | 1 |
| Kerr, DJ | 1 |
| Houlston, RS | 1 |
| Escott-Price, V | 1 |
| Cheadle, JP | 1 |
| Abdelmeniem, IM | 1 |
| El Eryan, IM | 1 |
| Nofal, A | 1 |
| Fouda, I | 1 |
| Omar, SS | 1 |
| Attwa, E | 1 |
| Khater, MH | 1 |
| Selim, HM | 1 |
| Essam, R | 1 |
| Khattab, FM | 1 |
| Samir, MA | 1 |
| Fiallo, P | 1 |
| Azad, A | 1 |
| Chionh, F | 1 |
| Jayarajan, J | 1 |
| Moore, AY | 1 |
| Wetzig, T | 1 |
| Beckheinrich, P | 1 |
| Rytter, M | 1 |
| Haustein, UF | 1 |
| NURSE, DS | 1 |
| Wallner, JS | 1 |
| Fitzpatrick, JE | 1 |
| Brice, SL | 1 |
| Jiaravuthisan, MM | 1 |
| Sasseville, D | 1 |
| Vender, RB | 1 |
| Murphy, F | 1 |
| Muhn, CY | 1 |
| Weinstein, GD | 2 |
| McCullough, JL | 1 |
| Eaglstein, WH | 1 |
| Golub, A | 1 |
| Cornell, RC | 1 |
| Stoughton, RB | 3 |
| Clendenning, W | 1 |
| Zackheim, H | 1 |
| Maibach, H | 1 |
| Kulp, KR | 1 |
| King, L | 1 |
| Baden, HP | 1 |
| Taylor, JS | 1 |
| Deneau, DD | 1 |
| Fredriksson, T | 2 |
| Düker, D | 1 |
| Lane-Brown, MM | 1 |
| Lowe, NJ | 1 |
| Nychay, S | 1 |
| Orenberg, EK | 1 |
| Korey, A | 1 |
| Bosman, B | 1 |
| Schissel, DJ | 1 |
| Elston, DM | 1 |
| de Jong, EM | 1 |
| Menke, HE | 1 |
| van Praag, MC | 1 |
| van De Kerkhof, PC | 1 |
| de Berker, D | 1 |
| Rees, RB | 3 |
| Dovzhanskiĭ, SI | 1 |
| Suvorov, AP | 1 |
| García Almagro, D | 1 |
| Bueno, C | 1 |
| Corripio, F | 1 |
| Lecona, M | 1 |
| Jaqueti, G | 1 |
| Szczeklik-Franek, A | 1 |
| Bober, A | 1 |
| Kubek, M | 1 |
| Abraham, D | 1 |
| Feuerman, EJ | 1 |
| Baker, H | 1 |
| du Vivier, A | 1 |
| Datskovskiĭ, BM | 1 |
| Masetkin, IP | 1 |
| Osnovina, NG | 1 |
| Gueissaz, F | 1 |
| Borradori, L | 1 |
| Dubertret, L | 1 |
| Rotstein, H | 1 |
| Baker, C | 1 |
| Alper, JC | 2 |
| Wiemann, MC | 2 |
| Rueckl, FS | 1 |
| McDonald, CJ | 2 |
| Calabresi, P | 2 |
| Abernethy, DR | 1 |
| Pearlman, DL | 2 |
| Youngberg, B | 2 |
| Engelhard, C | 2 |
| Schmied, E | 1 |
| Levy, PM | 1 |
| Falkson, G | 1 |
| Schnellen, B | 1 |
| Ehinger, H | 1 |
| Luger, A | 1 |
| Padilla, H | 1 |
| Barrett, JL | 1 |
| Sayers, P | 1 |
| Auerback, R | 1 |
| Ljunggren, B | 1 |
| Möller, H | 1 |
| Tsuji, T | 1 |
| Sugai, T | 1 |
| Schuppli, R | 2 |
| Weitgasser, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities[NCT03370406] | Phase 1 | 30 participants (Anticipated) | Interventional | 2018-08-03 | Recruiting | ||
| Subclinical Nail Involvement in Relevant Skin Diseases[NCT04092413] | 384 participants (Anticipated) | Observational | 2019-11-01 | Not yet recruiting | |||
| Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study.[NCT03263624] | Phase 4 | 30 participants (Anticipated) | Interventional | 2017-10-01 | Not yet recruiting | ||
| Randomized Controlled Trial of 308 nm Excimer Laser for Treatment of Nail Psoriasis[NCT02168933] | 8 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is an instrument that scores nail psoriasis severity. Severity for each nail is measured on a scale of 0-13, where crumbling, pitting, onycholysis and oil spots together are each graded 0-3, and other features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in lunula) are scored 0 (absent) or 1 (present). Higher score indicates more severe nail psoriasis with 13 being the most severe and 0 being no nail disease present. (NCT02168933)
Timeframe: at 16 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 6.3 |
| Sham | 6.0 |
this is a subjective patient reported scale, 0-100, where 100 is the most severe global assessment of the patient's nail psoriasis, and 0 is clear (no nail disease present). (NCT02168933)
Timeframe: at 16 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 58.6 |
| Sham | 55.4 |
9 reviews available for fluorouracil and Psoriasis
| Article | Year |
|---|---|
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders.
Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic | 2009 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; | 2007 |
Management of nail psoriasis.
Topics: Administration, Topical; Anti-Inflammatory Agents; Antifungal Agents; Cyclosporine; Dermatologic Age | 2000 |
Current dermatologic therapy.
Topics: Acne Vulgaris; Administration, Topical; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antifungal A | 1976 |
Newer treatment in dermatology.
Topics: Acne Vulgaris; Adrenal Cortex Hormones; Antifungal Agents; Antineoplastic Agents; Carotenoids; Derma | 1975 |
Psoriasis: a review. II.
Topics: Adrenal Cortex Hormones; Anthralin; Azathioprine; Azauridine; Fluorouracil; Humans; Hydroxyurea; Lom | 1975 |
[Nail psoriasis].
Topics: Administration, Topical; Adrenal Cortex Hormones; Cyclosporine; Fluorouracil; Humans; Nail Diseases; | 1992 |
The treatment of psoriasis.
Topics: Administration, Oral; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Bed Rest; Chroni | 1990 |
The action of antimetabolites in the skin: methotrexate for psoriasis.
Topics: Carcinoma, Basal Cell; Cell Division; DNA; Fluorouracil; Humans; Injections, Intradermal; Keratosis; | 1972 |
8 trials available for fluorouracil and Psoriasis
| Article | Year |
|---|---|
Topical calcipotriol combined with urea 20% versus intralesional injection of triamcinolone acetonide, 5-fluorouracil, and methotrexate in the treatment of nail psoriasis: A comparative study.
Topics: Calcitriol; Dermatologic Agents; Fluorouracil; Humans; Injections, Intralesional; Methotrexate; Nail | 2022 |
A clinical screening program for topical chemotherapeutic drugs in psoriasis.
Topics: Adult; Animals; Clinical Trials as Topic; Cycloheximide; Dermatologic Agents; Double-Blind Method; D | 1981 |
Intradermal fluorouracil and epinephrine injectable gel for treatment of psoriatic plaques.
Topics: Antimetabolites; Drug Therapy, Combination; Epinephrine; Female; Fluorouracil; Gels; Humans; Injecti | 1995 |
Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study.
Topics: Adult; Aged; Antimetabolites; Double-Blind Method; Female; Fluorouracil; Hand Dermatoses; Humans; Ma | 1999 |
Rationally designed combination chemotherapy for the treatment of patients with recalcitrant psoriasis.
Topics: Adult; Aged; Azauridine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; | 1985 |
Weekly psoriasis therapy using intralesional fluorouracil.
Topics: Administration, Topical; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Fluorouracil; | 1987 |
Weekly pulse dosing schedule of fluorouracil: a new topical therapy for psoriasis.
Topics: Administration, Topical; Adult; Clinical Trials as Topic; Double-Blind Method; Drug Administration S | 1986 |
Topical use of fluorouracil in the treatment of psoriasis.
Topics: Fluorouracil; Humans; Ointments; Psoriasis | 1972 |
35 other studies available for fluorouracil and Psoriasis
| Article | Year |
|---|---|
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Ne | 2022 |
Comparative efficacy of intralesional 5 flurouracil and intralesional triamcinolone acetonide in localized plaque psoriasis.
Topics: Drug Therapy, Combination; Fluorouracil; Humans; Hyperpigmentation; Injections, Intralesional; Keloi | 2022 |
Botulinum toxin type-A versus 5-fluorouracil in the treatment of plaque psoriasis: Comparative study.
Topics: Botulinum Toxins, Type A; Fluorouracil; Humans; Psoriasis; Recurrence; Treatment Outcome | 2021 |
Yellow nails as an adverse reaction to the topical use of 5-fluorouracil for the treatment of nail psoriasis.
Topics: Administration, Topical; Aged; Female; Fluorouracil; Humans; Immunosuppressive Agents; Psoriasis; Ye | 2009 |
Gallbladder squamous cell carcinoma in the setting of low-dose methotrexate use.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cholecystectomy, Lap | 2009 |
Erosion of psoriatic plaques: an uncommon side-effect of neoadjuvant 5-fluorouracil treatment of colon cancer.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Eruptions; Fluorouracil | 2002 |
Effect of antimetabolites on epidermal structures.
Topics: Antimetabolites; Epidermis; Fluorouracil; Hair; Humans; Mercaptopurine; Methotrexate; Psoriasis; Ski | 1963 |
Verrucous porokeratosis of Mibelli on the buttocks mimicking psoriasis.
Topics: Buttocks; Diagnosis, Differential; Fluorouracil; Humans; Male; Middle Aged; Porokeratosis; Psoriasis | 2003 |
Psoriatic nails and 5-fluorouracil.
Topics: Administration, Topical; Fluorouracil; Humans; Nail Diseases; Psoriasis | 1982 |
Investigations into sister chromatid exchange in patients under cytostatic therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Child; Child, Preschool; Cr | 1981 |
Scalp and nail psoriasis.
Topics: Dermatologic Agents; Fluorouracil; Humans; Nail Diseases; Psoriasis; Scalp Dermatoses | 1980 |
Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis.
Topics: Animals; Cell Differentiation; Cyclooxygenase Inhibitors; Cyclosporine; Dose-Response Relationship, | 1994 |
Topical 5-fluorouracil treatment for psoriatic trachyonychia.
Topics: Administration, Topical; Female; Fluorouracil; Humans; Middle Aged; Nail Diseases; Psoriasis | 1998 |
[Use of fluorafur in the therapy of various chronic dermatoses].
Topics: Adult; Aged; Chronic Disease; Fluorouracil; Humans; Male; Middle Aged; Neurodermatitis; Psoriasis; S | 1977 |
[Multiple clear cell acanthoma in a patient with psoriasis. Treatment with 5-fluorouracil].
Topics: Administration, Topical; Aged; Female; Fluorouracil; Humans; Papilloma; Psoriasis; Skin Neoplasms | 1979 |
[Clinical and histological studies of psoriatic lesions treated with 5% 5-fluorouracil ointment].
Topics: Adult; Female; Fluorouracil; Humans; Male; Middle Aged; Ointments; Psoriasis; Skin | 1979 |
[Local treatment of psoriatic nails with 5-fluorouracil].
Topics: Administration, Topical; Fluorouracil; Humans; Nail Diseases; Psoriasis | 1978 |
Psoriasis: clinical aspects and management.
Topics: Administration, Topical; Age Factors; Azauridine; Fluorouracil; Humans; Hydroxyurea; Mechlorethamine | 1976 |
An animal model for screening topical and systemic drugs for potential use in the treatment of psoriasis.
Topics: Administration, Topical; Animals; Cyclophosphamide; Disease Models, Animal; DNA; Drug Evaluation, Pr | 1975 |
[External use of cytostatics in psoriasis].
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Chlorambucil; Cyclophosphamide; Drug Evaluation; | 1975 |
Oral 5-fluorouracil in psoriasis: pharmacokinetic-pharmacodynamic relationships.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Resistance; Female; Fluoro | 1989 |
Transient rhabdomyolysis connected with topical use of 5-fluorouracil in a patient with psoriasis of the nails.
Topics: Administration, Topical; Adult; Fluorouracil; Humans; Male; Nail Diseases; Psoriasis; Rhabdomyolysis | 1986 |
Some aspects of the use of cytostatic drugs in dermatology.
Topics: Colchicine; Dactinomycin; Fluorouracil; Humans; Melanoma; Methotrexate; Mycosis Fungoides; Nitrogen | 1966 |
[Therapeutic possibilities in multiple epitheliomas of the trunk skin].
Topics: Arsenic; Carcinoma, Basal Cell; Electrocoagulation; Female; Fluorouracil; Humans; Long-Term Care; Ma | 1973 |
[5-Fluorouracil in the local treatment of psoriasis].
Topics: Adult; Aged; Anthracenes; Anti-Infective Agents, Local; Dermatologic Agents; Female; Fluorouracil; H | 1969 |
Topically applied fluorouracil in the treatment of psoriatic nails.
Topics: Administration, Topical; Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Nails; Psoria | 1974 |
Percutaneous absorption: a personal view.
Topics: Administration, Topical; Animals; Atropine; Fluorouracil; Hair; Humans; Hyperhidrosis; Injections, I | 1974 |
[Indications for fluorouracil in dermatology].
Topics: DNA; DNA Replication; Drug Evaluation; Fluorouracil; Humans; Keratoacanthoma; Keratosis; Neoplasms; | 1974 |
Unsuccessful fluorouracil treatment of recalcitrant pustular psoriasis.
Topics: Adult; Fluorouracil; Humans; Hydroxyurea; Male; Prednisone; Psoriasis | 1973 |
Fluorouracil cream (Efudix) in dermatology.
Topics: Fluorouracil; Humans; Keratosis; Psoriasis; Skin Diseases; Skin Neoplasms; Xeroderma Pigmentosum | 1973 |
Letter: Unsuccessful fluorouracil treatment of psoriasis.
Topics: Fluorouracil; Humans; Psoriasis | 1974 |
Topically administered fluorouracil in psoriasis.
Topics: Adolescent; Adult; Aged; Biopsy; Child; Epithelial Cells; Female; Fluorouracil; Humans; Male; Middle | 1972 |
[Practical use of immunosuppressive and cytostatic drugs in dermatological diseases].
Topics: Antineoplastic Agents; Azathioprine; Condylomata Acuminata; Fluorouracil; Humans; Immunosuppressive | 1970 |
[Treatment of dermatologic lesions using immunosuppressive agents and cytostatics].
Topics: Antineoplastic Agents; Azathioprine; Dermatomyositis; Fluorouracil; Humans; Immunosuppressive Agents | 1970 |
[Experiences with a cytostaticly active ointment in the dermatologic practice. (5 per cent--5-fluorouracil ointment)].
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lichen P | 1969 |